Is CLSN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

3,766 people get CLSN articles and Market Currents by email alert.

Get email alerts on CLSN »

HEADLINES:

Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO)

PR Newswire (Fri, 8:00AM)
Amarin & Celsion: Post-Earnings Roundup
Quoth the Raven • Wed, May 15 • 35 Comments
Celsion's Q1 Call: What You Need To Know
Quoth the Raven • Thu, May 9 • 4 Comments
Celsion Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Celsion: New Findings Show Act Of Desperation
Avi Greenberg • Thu, May 9 • 9 Comments
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update

PR Newswire (May 9, 2013)
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Celsion's A Fighter
Quoth the Raven • Wed, May 1 • 22 Comments
Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013

PR Newswire (May 1, 2013)
Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013

PR Newswire (May 1, 2013)
Are We Watching Celsion Rise From The Grave?
Quoth the Raven • Tue, Apr 23 • 17 Comments
Celsion Corporation Provides Business Update

PR Newswire (Apr 23, 2013)
BSD Medical News To Create A Spark
Amy Baldwin • Thu, Apr 11 • 14 Comments
3 Biotechs And The Feuerstein-Ratain Rule
Equity Options Guru • Tue, Apr 9 • 32 Comments
Celsion's ThermoDox May Be Back In Play
Quoth the Raven • Mon, Mar 18 • 7 Comments
5 Investing Tricks Of The Trade For Your Arsenal
Quoth the Raven • Mon, Mar 18 • 56 Comments
Celsion Corporation's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Mar 18
Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update

PR Newswire (Mar 18, 2013)
Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013

PR Newswire (Mar 12, 2013)
4 Biotech Stocks Looking To Heat Up In Time For Summer
Craig Keolanui • Sun, Mar 10 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

Amarin & Celsion: Post-Earnings Roundup
Quoth the Raven • Wed, May 15 • 35 Comments
Celsion's Q1 Call: What You Need To Know
Quoth the Raven • Thu, May 9 • 4 Comments
Celsion: New Findings Show Act Of Desperation
Avi Greenberg • Thu, May 9 • 9 Comments
Celsion's A Fighter
Quoth the Raven • Wed, May 1 • 22 Comments
Are We Watching Celsion Rise From The Grave?
Quoth the Raven • Tue, Apr 23 • 17 Comments
Celsion's ThermoDox May Be Back In Play
Quoth the Raven • Mon, Mar 18 • 7 Comments
Celsion Has Multi-Bagger Potential From Here
Quoth the Raven • Sun, Mar 10 • 29 Comments
Celsion Dilutes By Fifty Percent
Red Acre Investments • Fri, Feb 22 • 21 Comments
After Phase III Failure, Celsion Is Still Worthless
Chimera Research Group • Tue, Feb 12 • 12 Comments
Will Celsion Survive?
StockRiters • Tue, Feb 12 • 5 Comments
Is Delcath The Post-Celsion Play On Liver Cancer?
Brian L. Wilson • Mon, Feb 4 • 19 Comments
Celsion Stock Blown Apart On Thermodox Phase III Data
Brian L. Wilson • Sat, Feb 2 • 26 Comments
Celsion's 'Bad Beat' : 4 'Tells' That Longs Missed
Quoth the Raven • Thu, Jan 31 • 59 Comments
Celsion Phase III Failure: What Went Wrong?
Heisenberg Principle • Thu, Jan 31 • 40 Comments
Can Celsion Survive After Imploding Over Phase III Results?
Quoth the Raven • Thu, Jan 31 • 62 Comments
As Celsion Ventures Into China, All Eyes Are On Phase III Trials
Matt Schilling • Tue, Jan 22 • 15 Comments
Celsion Appears To Take A Big Step In The Right Direction
Quoth the Raven • Tue, Jan 22 • 20 Comments
Refocused, Reframed And Patiently Awaiting Celsion's Real Results After This Week's Chaos
Quoth the Raven • Fri, Jan 18 • 23 Comments
Taking Some Profits In Celsion
InsiderInsights • Wed, Jan 16 • 31 Comments
Recalculating Celsion's Upcoming Results
James Stocklasar Thomas Jr. • Mon, Jan 14 • 33 Comments

Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
BSD Medical News To Create A Spark
Amy Baldwin • Thu, Apr 11 • 14 Comments
3 Biotechs And The Feuerstein-Ratain Rule
Equity Options Guru • Tue, Apr 9 • 32 Comments
5 Investing Tricks Of The Trade For Your Arsenal
Quoth the Raven • Mon, Mar 18 • 56 Comments
4 Biotech Stocks Looking To Heat Up In Time For Summer
Craig Keolanui • Sun, Mar 10 • 4 Comments
3 Biotech Stocks Ready To Rally
BuySellShort • Wed, Mar 6 • 8 Comments
Biotech Stocks With Recent Developments: 3 To Consider, 1 To Avoid
Brian L. Wilson • Wed, Mar 6 • 9 Comments
2 Biotech Superstars For 2013
Equity Options Guru • Tue, Mar 5 • 30 Comments
A 2013 Diversified Bullish Portfolio In 10 Positions
Quoth the Raven • Thu, Feb 28 • 59 Comments
Following Crashing Biotechs - 5 Bargains To Consider
Craig Keolanui • Tue, Feb 26 • 5 Comments
A Biotech Winner For 2013
Equity Options Guru • Thu, Feb 21 • 15 Comments
The War Over Amarin: Feuerstein Battles Heisenberg And How I'd Invest It
Quoth the Raven • Wed, Feb 20 • 22 Comments
China Biotech In Review: Cardinal Health Uses M&A To Add Drug Distribution Reach
ChinaBio Today • Sun, Feb 10
Speculative Biotech Stocks That Could Bounce
BuySellShort • Thu, Feb 7 • 23 Comments
Small Pharmaceuticals With Near Term Catalysts - Durect And Inovio
BuySellShort • Mon, Feb 4 • 11 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Fri, Feb 1 • 6 Comments
VIX - Options Volatility And Market Sonar: Tuesday Recap
Erick McKitterick • Tue, Jan 29 • 8 Comments
Biopharma Catalyst Trades To Watch For This Week
Scott Matusow • Mon, Jan 28 • 23 Comments
Phase III Data Will Rock These 2 Bio Stocks
Brian L. Wilson • Mon, Jan 28 • 7 Comments
China Biotech In Review: 2012 China Life Science VC, M&A, And Partnering Climb
ChinaBio Today • Sun, Jan 27 • 5 Comments

Celsion Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9
Celsion Corporation's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Mar 18
Celsion's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 12, 2012
Celsion Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Aug 14, 2012

Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO)

PR Newswire (Fri, 8:00AM)
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update

PR Newswire (May 9, 2013)
Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013

PR Newswire (May 1, 2013)
Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013

PR Newswire (May 1, 2013)
Celsion Corporation Provides Business Update

PR Newswire (Apr 23, 2013)
Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update

PR Newswire (Mar 18, 2013)
Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013

PR Newswire (Mar 12, 2013)
Celsion Corporation Announces $15 Million Registered Direct Offering

PR Newswire (Feb 22, 2013)
Celsion Corporation Provides an Update Regarding ThermoDox® Agreements with Zhejiang HISUN Pharmaceutical Company for China

PR Newswire (Feb 5, 2013)
Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer

PR Newswire (Jan 31, 2013)
Celsion Corporation to Host Conference Call and Webcast on January 31, 2013 at 8:00 AM EST to Present Top-Line Data from its Pivotal Phase III HEAT Study

PR Newswire (Jan 30, 2013)
Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Enter Into Technology Development Agreement for ThermoDox® for the Greater China Territory

PR Newswire (Jan 22, 2013)
The Technical Indicator: Bullish backdrop vies with Apple’s downturn

at MarketWatch.com (Jan 15, 2013)
Celsion Corporation Reports Third Quarter 2012 Financial Results and Business Update

Marketwire (Nov 12, 2012)
Celsion Announces Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer Reaches Target Number of Events for Unblinding

Marketwire (Nov 9, 2012)
Celsion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

Marketwire (Nov 6, 2012)
Celsion Corporation to Hold Third Quarter 2012 Financial Results Conference Call on Monday, November 12, 2012

Marketwire (Nov 2, 2012)
Celsion Announces DIGNITY Study Data Presented at 2012 Congress for European Society of Medical Oncology

Marketwire (Oct 1, 2012)
Celsion Announces ThermoDox(R) Presentation at the 2012 Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe

Marketwire (Sep 18, 2012)
Celsion Announces Independent Data Monitoring Committee Completes Last Intermediate Review of Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer Prior to Final Data

Marketwire (Sep 14, 2012)

CLSN vs. ETF Alternatives

Company Description

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 9:08 AM Celsion (CLSN) jumps 14% premarket after the company says data from a Phase III HEAT study suggests ThermoDox combined with radio frequency ablation warrants "further investigation and development … as a first line treatment for hepatocellular carcinoma." (PR) 1 Comment [Healthcare, On the Move]
Thursday, May 9, 9:39 AM Celsion (CLSN): Q1 EPS of -$0.12 beats by $0.04. Revenue of $125K misses by $65.K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 23, 9:03 AM Celsion Corp (CLSN) is moving higher in pre-trading on comments from the company that its experimental cancer drug, Thermodox, shows it may now in fact be viable for the treatment of liver cancer. The comments come just months after the company warned of the drug's limited prospects, causing the stock to crater 81% in one day in January after the company suggested the drug failed to significantly slow the progression of liver cancer in a late-stage trial. Shares +14%. 1 Comment [Healthcare, On the Move, Global & FX]
Monday, March 18, 9:10 AM Premarket gainers: FU +19%. PRWT +9%. GALE +7%. CLSN +7%.
Losers: AMBO -15%. INCY -12%. FBN -11%. JVA -8%. NBG -6%. ING -6%. NVO -5%. Comment! [On the Move]
Friday, March 8, 9:10 AM Premarket gainers: P +25%. TPX +9%. BVSN +7%. ANN +8%. CLSN +5%. HRB +5%.
Losers: SKUL -17%. MXWL -15%. MED -9%. GOL -6%. Comment! [On the Move]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
Monday, February 11, 9:15 AM Premarket gainers: CLSN +9%. AUDC +7%.
Losers: NVO -14%. RDN -7%. CZR -7%. HEK -5%.
1 Comment [On the Move]
Monday, February 4, 12:45 PM Midday top 10 gainers: HPTX +31%. APKT +22%. EBOD +16%. PGRX +15%. SONS +14%. PC +11%. EDAP +9%. ORRF +10%. HMY +9%. TAOM +9%.
Midday top 10 Losers: INUV -13%. CLSN -13%. SED -12%. CYTK -8%. VVI -9%. CTC -8%. PRIS -8%. PERI -8%. BLIN -8%. CFBK -8%. Comment! [On the Move]
Monday, February 4, 12:33 PM Celsion (CLSN -11.4%) sinks again today after noting in a SEC filing that it's entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to sell $25M worth of shares, from time to time. The stock cratered last week on news that its liver cancer drug TheromDox had failed its latest clinical trials. 2 Comments [Healthcare, On the Move]
Friday, February 1, 4:39 PM Shares of Celsion (CLSN) added to yesterday's 79% free fall today, closing out the day with an additional 12.6% hit after touching a new 52-week low of $1.25 earlier. The downturn was sparked on Thursday after the company announced that ThermoDox did not meet the primary endpoint in a Phase III study in patients with hepatocellular carcinoma also known as primary liver cancer. 4 Comments [Healthcare, On the Move]
Friday, February 1, 12:45 PM Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move]
Friday, February 1, 9:10 AM Premarket gainers: ADNC +30%. TSYS +15%. RAD +9%. CTRP +8%. EDAP +7%. ALU +6%. DELL +6%. VVUS +5%. PRGO +5%.
Losers: ECTE -35%. OTT -23%. LTM -16%. SDR -11%. OCZ -8%. CLSN -7%. ALKS -7%. NMM -6%. TLAB -5%. Comment! [On the Move]
Thursday, January 31, 3:18 PM Roth Capital is stepping to the sidelines on Celsion (CLSN -81%), cutting the shares to Neutral on the back of the failed trial results on its experimental liver cancer drug ThermoDox. The technology failed to significantly slow the progression of liver cancer by what appears to be a wide marging, and calls into doubt the drug's near-term viability. 1 Comment [Healthcare, On the Move]
Thursday, January 31, 12:45 PM Midday top 10 gainers: ORCC +82%. WMS +52%. FTNT +24%. HHS +22%. EDMC +18%. BTUI +18%. JDSU +18%. PBI +17%. CSII +16%. SGI +16%.
Midday top 10 Losers: CLSN -81%. LQDT -24%. STZ -20%. NVGN -18%. FIO -16%. HALO -16%. RDEN -14%. USAK -13%. HAR -13%. JBSS -12%. Comment! [On the Move]
Thursday, January 31, 9:23 AM Celsion (CLSN) -78.1% premarket on news that ThermoDox in combination with radiofrequency ablation did not meet the primary endpoint of the Phase III HEAT Study in patients with primary liver cancer. The study was designed to show a 33% improvement in progression-free survival. CLSN is conducting additional analyses of data from the trial to assess the future strategic value of ThermoDox. 5 Comments [Healthcare, On the Move]
Thursday, January 31, 9:13 AM Premarket gainers: ORCC +82%. WMS +55%. FTNT +20%. SGMS +15%. JDSU +14%. KERX +14%. ALGN +13%. SWKS +13%. CTXS +12%. ERIC +11%. DCTH +7%. PBI +8%. QCOM +6%. ALU +6%. CXS +6%. FNSR +6%. LVS +6%. UA +5%. IGT +5%.
Losers: CLSN -79%. LQDT -15%. FIO -14%. RIMM -7%. AFFY -7%. RMD -6%. FB -6%. VNR -5%. 1 Comment [On the Move]

Quoth the Raven
More insider buying at $CLSN, two weeks and running now. $SPY
6 hours ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
Celsion's support around .95 seems to be the real deal. $CLSN $SPY http://seekingalpha.com/a/usbh
May 15, 4:01 PM
Reply (2)

• !Report Abuse
View all 2 replies
jcllier3: QTR, any thoughts on $DCTH at $0.40?
May 15, 4:15 PM
• !Report Abuse
Quoth the Raven: Personally, I wouldn't touch Delcath.
Thu, 6:11 PM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
More insider buying at $CLSN.
May 13, 5:51 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
Insiders are buying Celsion $CLSN on the open market at .92, so am I. http://bit.ly/15wDowJ
May 10, 2:47 PM
Reply (1)

• !Report Abuse
View all 1 replies
RSI Raistlin: CLSN seems sketchy though after fail and cash burn. Plus a 3.3% increase in holdings and under $5k worth of stock isn't a strong statement.
May 10, 6:30 PM
• !Report Abuse
Add a reply...

140 characters

353276
looks good $CLSN beats the the street by .04
May 9, 9:13 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
Can $CLSN make the run to 1.50 on earnings this week? http://seekingalpha.com/a/tsbn
May 7, 2:42 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Quoth the Raven
The Celsion $CLSN bull in me is coming alive again. Earnings this Wednesday! http://seekingalpha.com/a/tsbn
May 6, 1:08 PM
Reply (2)

• !Report Abuse
View all 2 replies
JMattius: Taking profits Quoth? Nice run so far. Congrats.
May 7, 10:48 AM
• !Report Abuse
Quoth the Raven: My $1 calls did great. I'm going to hold through earnings.
May 7, 10:53 AM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
Celsion's a Fighter http://seekingalpha.com/a/tsbn $CLSN
May 2, 8:21 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

TipRanks
Worst recommendation of 2013! 80% loss $CLSN $PPHM http://seekingalpha.com/p/12sbt
Apr 30, 2:01 PM
Reply (5)

• !Report Abuse
View all 5 replies
TipRanks: Perkins - thanks for the kind words! let us know what cool features should we add.
May 1, 12:15 AM
• !Report Abuse
353276: $CLSN beats the street by .04
May 9, 9:15 AM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
$CLSN has multi-bagger potential from here. Earnings on Monday.
Mar 14, 5:33 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Quoth the Raven
Celsion's support around .95 seems to be the real deal. $CLSN $SPY http://seekingalpha.com/a/usbh
May 15, 4:01 PM
Reply (2)

• !Report Abuse
View all 2 replies
jcllier3: QTR, any thoughts on $DCTH at $0.40?
May 15, 4:15 PM
• !Report Abuse
Quoth the Raven: Personally, I wouldn't touch Delcath.
Thu, 6:11 PM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
Insiders are buying Celsion $CLSN on the open market at .92, so am I. http://bit.ly/15wDowJ
May 10, 2:47 PM
Reply (1)

• !Report Abuse
View all 1 replies
RSI Raistlin: CLSN seems sketchy though after fail and cash burn. Plus a 3.3% increase in holdings and under $5k worth of stock isn't a strong statement.
May 10, 6:30 PM
• !Report Abuse
Add a reply...

140 characters

TipRanks
Worst recommendation of 2013! 80% loss $CLSN $PPHM http://seekingalpha.com/p/12sbt
Apr 30, 2:01 PM
Reply (5)

• !Report Abuse
View all 5 replies
TipRanks: Perkins - thanks for the kind words! let us know what cool features should we add.
May 1, 12:15 AM
• !Report Abuse
353276: $CLSN beats the street by .04
May 9, 9:15 AM
• !Report Abuse
Add a reply...

140 characters

Quoth the Raven
The Celsion $CLSN bull in me is coming alive again. Earnings this Wednesday! http://seekingalpha.com/a/tsbn
May 6, 1:08 PM
Reply (2)

• !Report Abuse
View all 2 replies
JMattius: Taking profits Quoth? Nice run so far. Congrats.
May 7, 10:48 AM
• !Report Abuse
Quoth the Raven: My $1 calls did great. I'm going to hold through earnings.
May 7, 10:53 AM
• !Report Abuse
Add a reply...

140 characters

joeg1969
Three Bio stocks to watch for on Monday $MNKD $CLSN $TZYM
Feb 9, 6:19 PM
Reply (4)

• !Report Abuse
View all 4 replies
joeg1969: Definetly !!!!!!!!!!!!Willl see how things play out for a bit before adding .......
Feb 10, 1:28 AM
• !Report Abuse
joe kelly: Bought some last week.
Feb 10, 4:14 PM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
finally seeing green on my protfolio, $ABIO,$AUY,$CLSN what a great day..... congrats to $ISIS
Jan 30, 10:41 AM
Reply (5)

• !Report Abuse
View all 5 replies
LEIGHDIST: got hit enough with amrn i don't take a chance anymore anytime i see green i take big or small, i think i will do like you get out on abio
Jan 31, 11:24 AM
• !Report Abuse
LEIGHDIST: Joe ended up selling my portion of abio also at .73 took a gain also but i will go back as soon as it drops hopefully under .50
Feb 5, 3:28 PM
• !Report Abuse
Add a reply...

140 characters

Nick Chiu
$CLSN study failed. trading at $1.68 pre-market
Jan 31, 9:13 AM
Reply (10)

• !Report Abuse
View all 10 replies
Nick Chiu: IV = Implied Volatility for options http://bit.ly/RfrDSu
Jan 31, 10:44 AM
• !Report Abuse
bilayy: thanks!
Feb 4, 2:45 PM
• !Report Abuse
Add a reply...

140 characters

jason2713
$CLSN - disasters. A Michael Bryant serving. Solid.
Jan 31, 10:40 AM
Reply (1)

• !Report Abuse
View all 1 replies
adawg304: LOL
Jan 31, 11:10 AM
• !Report Abuse
Add a reply...

140 characters

leokingdom
$CLSN The stock drops 78% in pre-market
Jan 31, 8:58 AM
Reply (1)

• !Report Abuse
View all 1 replies
bilayy: WOW!!!! Time to Buy??? Maybe YES!
Jan 31, 10:37 AM
• !Report Abuse
Add a reply...

140 characters

Nick Chiu
$CLSN, looking for a better options strategy..
Jan 25, 1:42 AM
Reply (14)

• !Report Abuse
View all 14 replies
Nick Chiu: Thumpy, that is a good bet for volatility collapse and works well if CLSN stays or goes up..
Jan 29, 9:21 AM
• !Report Abuse
Nick Chiu: fair value calculation.. http://on.mktw.net/117ugqy
Jan 29, 9:41 AM
• !Report Abuse
Add a reply...

140 characters

angrygiraffe
If $CLSN is going to either drop to $1 or less or shoot up to $20+, why not just straddle with short+calls? Am I missing something?
12/28/12
Reply (3)

• !Report Abuse
View all 3 replies
angrygiraffe: True. I guess I'm just wondering how accurate these predictions are. I can see the low end being the case. Not sure about high end.
12/29/12
• !Report Abuse
noueis: Right now the premiums are so large that a drop wouldn't net you much. You would have to get below a dollar just to break even
Jan 3, 5:16 AM
• !Report Abuse
Add a reply...

140 characters

Jason F
My thoughts on $CLSN short and long term http://stks.co/kHKu
12/22/12
Reply (7)

• !Report Abuse
View all 7 replies
JMattius: Agreed. I will watch closely on the 26th. I jumped in today so hopefully she still has some room to run. Have a merry Christmas.
12/24/12
• !Report Abuse
Jason F: You too!
12/24/12
• !Report Abuse
Add a reply...

140 characters

biomanbaba
SHORT MEDIA CAMPAIGN under way..it is design to strike unwarranted FEAR into the minds of $CLSN shareholders DONT LET THEM TAKE YOUR MONEY
12/15/12
Reply (1)

• !Report Abuse
View all 1 replies
Avoc: Though, I welcome the cheaper shares. If it goes under 7.50 I will be adding.
12/17/12
• !Report Abuse
Add a reply...

140 characters

Biotech Sage
$CLSN
12/15/12
Reply (1)

• !Report Abuse
View all 1 replies
biomanbaba: SHORT MEDIA CAMPAIGN under way...it is design to strike unwarranted FEAR into the minds of CLSN shareholders DONT LET THEM TAKE YOUR MONEY
12/15/12
• !Report Abuse
Add a reply...

140 characters

John Rayhall
Will CLSN ever sell off so I can buy some? Sheesh ON FIRE!
8/24/12
Reply (23)

• !Report Abuse
View all 23 replies
DAG1996: yeah. if we had gotten one more down day for the whole market, i think CLSN would've hit $4, but the market took off and puled it back up
9/7/12
• !Report Abuse
John Rayhall: It's on fire today wow oh well
9/7/12
• !Report Abuse
Add a reply...

140 characters

CLSN Celsion Corporation

CLSN

Celsion Corporation